Publications by authors named "Alan Sandler"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

19,641

Total Likes

195

Extended Reach

91,447

Social Features

15
I
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer.
Mitchell S von Itzstein, Sawsan Rashdan, Suzanne E Dahlberg, David E Gerber, Alan B Sandler

Oncologist· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.
Namrata S Patil, Wei Zou, Simonetta Mocci, Alan Sandler, Marcus Ballinger

PLoS One· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Roy S Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, Alain Vergnenegre, Alan Sandler

N Engl J Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
Robert Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez-Abreu, Alan Sandler

J Thorac Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, Herbert I Hurwitz, Alan B Sandler, David Miles, Robert L Coleman

Cancer Treat Rev· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with mutations.
Martin Reck, Geetha Shankar, Anthony Lee, Shelley Coleman, Mark McCleland, Alan Sandler

Expert Rev Respir Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Alan Sandler

Lancet Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Shirish M Gadgeel, Rimas V Lukas, Jerome Goldschmidt, Paul Conkling, Keunchil Park, Alan Sandler

Lung Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.
David R Gandara, Joachim von Pawel, Julien Mazieres, Richard Sullivan, Åslaug Helland, Alan Sandler

J Thorac Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Leora Horn, Aaron S Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Alan Sandler

N Engl J Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
David R Spigel, Jamie E Chaft, Scott Gettinger, Bo H Chao, Luc Dirix, Alan Sandler

J Thorac Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Marcin Kowanetz, Wei Zou, Scott N Gettinger, Hartmut Koeppen, Mark Kockx, Alan Sandler

Proc Natl Acad Sci U S A· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, Diego Cortinovis, Thomas Karagiannis, Alan Sandler

Clin Lung Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Leora Horn, Scott N Gettinger, Michael S Gordon, Roy S Herbst, Leena Gandhi, Alan Sandler

Eur J Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, Achim Rittmeyer, David R Gandara, Alan Sandler

J Thorac Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
Laurent Claret, Jin Y Jin, Charles Ferté, Helen Winter, Sandhya Girish, Alan Sandler

Clin Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
Philip Bonomi, Gideon Blumenthal, Andrea Stern Ferris, David J Stewart, Wendy K D Selig, Alan Sandler

J Thorac Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Alan Sandler

N Engl J Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent progress in therapeutic antibodies for cancer immunotherapy.
Anthony Lee, Shawn Sun, Alan Sandler, Tien Hoang

Curr Opin Chem Biol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Solange Peters, Scott Gettinger, Melissa L Johnson, Pasi A Jänne, Marina C Garassino, Alan Sandler

J Clin Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospects and progress of atezolizumab in non-small cell lung cancer.
Johan Vansteenkiste, Els Wauters, Keunchil Park, Achim Rittmeyer, Alan Sandler

Expert Opin Biol Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Alan Sandler

Lancet· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
Kelong Han, Laurent Claret, Alan Sandler, Asha Das, Jin Jin

BMC Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Alan Sandler

Lancet· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis